Navigation Links
Advance Nanotech Reports First Quarter 2008 Financial Results
Date:5/19/2008

Company reported a net loss of $1.1 million in the three months ended March 31, 2008 compared to a net loss of $2.4 million for the comparable period in 2007, representing a decrease of $1.3 million, or 55 percent. In 2008, the Company had a net loss of $0.03 cents per basic share, compared with a net loss of $0.07 cents per basic share for the same quarter in 2007. Revenue increased by $531,000 while operating expenses decreased by $300,000 and the Company had a gain of $534,000 from minority interest related to subsidiaries' losses.

Operating expenses during the first quarter of 2008 totaled approximately $2.8 million, a decrease of approximately 10 percent over the first quarter of 2007. The Company anticipates further cost reductions over the next several quarters as it completes the anticipated Owlstone exchange agreement that was previously announced and eliminates all redundant operational costs. Additional cost reductions may be achieved as the Company refocuses exclusively on the costs associated with operating its Owlstone business, and relieves itself of any future financial responsibilities associated with the current portfolio of nanotechnologies. As such, the Company anticipates a material operating cost reduction over the next several quarters.

Interest expense incurred during the first quarter of 2008 increased by approximately $146,000 over the first quarter of 2007 to $166,000. The increase in interest expense was due to the issuance of $6.7 million of 8% senior secured convertible notes in December 2007 and February 2008.

Total assets remained essentially unchanged from the prior quarter at $6.0 million as of March 31, 2008. Cash and equivalents on March 31, 2008 were $2.3 million, an increase of approximately $462,000 from December 31, 2007. Total liabilities increased from $11.9 million to $14.6 million during the first quarter of 2008 predominately due to the issuance of $2.7 million of convertible notes during the quarter.
'/>"/>

SOURCE Advance Nanotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Advanced BioHealing and Regenesis Biomedical Form Co-Promotion Alliance for Dermagraft(R)
2. Boston Scientific Announces European Approval and Market Launch of New Family of Advanced Pacemakers
3. Advanced Life Sciences Announces First Quarter 2008 Financial Results
4. Battelle Collaborating With Korean Partners to Advance Energy Efficiency and Health and Life Sciences Initiatives in Korea
5. Advanced Life Sciences to Host 2008 First Quarter Financial Results Conference Call and Webcast
6. Regenesis Biomedical Advances Corporate Strategy by Appointing Vice President of Marketing
7. Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
8. Avastin Used in Combination with Drugs from Bristol-Myers Squibb Has Advantages in Survival Rates Over the Current Sales-Leading Therapy for Advanced Ovarian Cancer
9. Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO
10. Advanced Life Sciences Regains Compliance With Nasdaq Listing Requirements
11. Human Genome Sciences Advances Oncology Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... G-CON Manufacturing, Inc., ... of their 2nd generation cell therapy POD® design. The 2nd generation portfolio not ... represents a new POD® design. , “G-CON first offered our miniPOD CT ...
(Date:7/29/2015)... CHICAGO , July 29, 2015  AmnioChor Inc., ... cell technology, is very pleased to announce that the ... has agreed to invest in their seed round ... OmniBank placental tissue storage capabilities. AmnioChor,s ... placenta, and the human stem cells living within those ...
(Date:7/29/2015)... , July 29, 2015  Indivior PLC (LON: ... for naloxone nasal spray was accepted and received Priority ... for the treatment of opioid overdose. This naloxone nasal ... specially formulated for optimal absorption into the nasal mucosa. ... minimal training so individuals may be better equipped to ...
(Date:7/29/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ) ... optimized Erk inhibitor molecule for development, thus achieving ... new class of potential cancer therapies. ... for therapeutic intervention in cancer. Recently approved compounds ... B-Raf and Mek inhibitors. Erk inhibitors may be ...
Breaking Biology Technology:G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... Mass.--Folding paper into shapes such as a crane or ... imagine trying to fold something that,s about a hundred ... it to use as an electronic device. , ... professor of mechanical engineering, is developing the basic principles ...
... Inc. (NASDAQ: VSGN ; TSX:VAS) today reported the results ... All dollar amounts referenced herein are in Canadian dollars unless ... cash equivalents totaled $8.6 million, compared with $23.5 million at ... As of January 31, 2009, our cash balance was $8.5 ...
... Feb. 27 Arkion(R) Life Sciences has received a ... Treatment in Louisiana effective March 1, 2009. The EPA ... protect field and sweet corn from marauding blackbirds and ... Avitec, Avipel(R) is applied to corn seed before planting ...
Cached Biology Technology:MIT uses nano-origami to build tiny electronic devices 2MIT uses nano-origami to build tiny electronic devices 3Vasogen Announces 2008 Year-End Results 2Vasogen Announces 2008 Year-End Results 3Vasogen Announces 2008 Year-End Results 4Vasogen Announces 2008 Year-End Results 5Vasogen Announces 2008 Year-End Results 6Vasogen Announces 2008 Year-End Results 7Vasogen Announces 2008 Year-End Results 8Vasogen Announces 2008 Year-End Results 9Vasogen Announces 2008 Year-End Results 10Vasogen Announces 2008 Year-End Results 11Crisis Exemption Granted to Market Avipel(R) Corn Seed Treatment in Louisiana 2
(Date:7/31/2015)... , Kina, 31. juli 2015 Den 10. ... afholdt af BGI fra den 22. - 25. oktober i ... Konferencen fejrer sin 10-års fødselsdag i år. Siden starten ... indflydelsesrige årlige møder på ,omik,-feltet, og er en af ... ICG-10 fokuserer på nylige gennembrud og fremskridt ...
(Date:7/31/2015)... , 31 de julio de 2015 ... (ICG-10,  www.icg-10.org ) del 22 al 25 de octubre ... La conferencia celebra su décimo aniversario este ... convertido en una de las reuniones anuales más influyentes ... es una de las conferencias científicas más dinámicas, entusiastas ...
(Date:7/31/2015)... China , 31 de julho de 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) será realizada pela BGI de 22-25 ... . A conferência está celebrando seu ... em 2006, a ICG se tornou uma das reuniões ... um dos encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... Strasbourg 18/04/12 - Technology has transformed the way humans interact ... big ideas that will drive growth in marine and maritime ... and policy will gather at the 3rd Marine Board Forum ... Marine Board has convened this flagship event on the understanding ...
... April 2012 -- Several new studies that may help ... individual patients and of their tumors are being presented ... "A major goal of lung cancer treatment is ... Fiona Blackhall from The Christie NHS Foundation Trust in ...
... can be used to boost an enzyme,s function by as much ... detergents and a host of other products. In a paper ... team led by Pratul Agarwal of the Department of Energy,s Oak ... nature and it happens in the blink of an eye. ...
Cached Biology News:New technologies for a blue future 2Advances in personalized medicine for lung cancer 2Advances in personalized medicine for lung cancer 3Advances in personalized medicine for lung cancer 4Advances in personalized medicine for lung cancer 5ORNL process improves catalytic rate of enzymes by 3,000 percent 2